

Title (en)  
COMPOSITION AND METHOD FOR REGULATION OF BODY WEIGHT AND ASSOCIATED CONDITIONS

Title (de)  
ZUSAMMENSETZUNG UND VERFAHREN ZUR REGULATION DES KÖRPERGEWICHTES UND DAMIT ZUSAMMENHÄNGENDER ZUSTÄNDE

Title (fr)  
COMPOSITION ET PROCEDES DE REGULATION DU POIDS CORPOREL ET DES PATHOLOGIES ASSOCIEES

Publication  
**EP 1137340 A4 20051221 (EN)**

Application  
**EP 99965208 A 19991209**

Priority

- US 9929337 W 19991209
- US 11158198 P 19981209
- US 14630699 P 19990729
- US 14630599 P 19990729
- US 14630499 P 19990729
- US 14630399 P 19990729
- US 14630299 P 19990729
- US 14630199 P 19990729
- US 14630099 P 19990729
- US 14629999 P 19990729
- US 37482799 A 19990812

Abstract (en)  
[origin: WO0033658A1] Described are methods and compositions for regulating body weight and/or regulating the rate of weight gain or loss, and particularly, for treating or preventing obesity. Specifically, methods of administering varying levels of circulating proopiomelanocortin peptides or analogs thereof to an animal, alone or in combination with leptin or other body weight regulating agents are disclosed. Methods and compositions for treating a variety of disorders associated with or caused by undesirable body weight are also described. Also described are methods for identifying compounds useful for regulation of body weight and associated conditions. In particular, methods are disclosed for identification of compounds that preferentially bind to and/or activate peripheral melanocortin receptors and which minimize binding and/or activation of central melanocortin receptors. Also described is a genetically modified non-human animal model for studying the peripheral and central pathways of energy homeostasis. Also disclosed are methods of identifying compounds for regulating such pathways and a POMC mutant mouse.

IPC 1-7  
**G01N 33/00**; **A01K 67/027**; **A61K 38/03**; **A61P 3/04**; **A61P 25/00**; **A61P 43/00**

IPC 8 full level  
**A01K 67/00** (2006.01); **A61K 38/03** (2006.01); **C07K 14/665** (2006.01); **C07K 14/705** (2006.01); **G01N 33/00** (2006.01)

CPC (source: EP)  
**A61P 3/04** (2017.12); **A61P 25/00** (2017.12); **A61P 43/00** (2017.12); **C07K 14/665** (2013.01); **C07K 14/705** (2013.01)

Citation (search report)

- [Y] WO 9810068 A2 19980312 - UNIV OREGON HEALTH SCIENCES [US], et al
- [Y] POGGIOLI R ET AL: "ACTH-(1-24) and alpha-MSH antagonize feeding behaviour stimulated by kappa opiate antagonists", PEPTIDES, ELSEVIER, AMSTERDAM, US, vol. 7, no. 5, 1986, pages 843 - 848, XP009018115, ISSN: 0196-9781
- [Y] FAN W ET AL: "ROLE OF MELANOCORTINERGIC NEURONS IN FEEDING AND THE AGOUTI OBESITY SYNDROME", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 385, 9 January 1997 (1997-01-09), pages 165 - 168, XP002072475, ISSN: 0028-0836
- [Y] HUSZAR D ET AL: "TARGETED DISRUPTION OF THE MELANOCORTIN-4 RECEPTOR RESULTS IN OBESITY IN MICE", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 88, no. 1, 10 January 1997 (1997-01-10), pages 131 - 141, XP000877328, ISSN: 0092-8674
- [Y] "A FRAMESHIFT MUTATION IN HUMAN MC4R IS ASSOCIATED WITH A DOMINANT FORM OF OBESITY", NATURE GENETICS, NEW YORK, NY, US, vol. 20, no. 2, October 1998 (1998-10-01), pages 113 - 114, XP000866527, ISSN: 1061-4036
- [Y] "A FRAMESHIFT MUTATION IN MC4R ASSOCIATED WITH DOMINANTLY INHERITED HUMAN OBESITY", NATURE GENETICS, NEW YORK, NY, US, vol. 20, no. 2, October 1998 (1998-10-01), pages 111 - 112, XP000866528, ISSN: 1061-4036
- [Y] CHAGNON YVON C ET AL: "Linkage and association studies between the melanocortin receptors 4 and 5 genes and obesity-related phenotypes in the Quebec Family Study", MOLECULAR MEDICINE (NEW YORK), vol. 3, no. 10, October 1997 (1997-10-01), pages 663 - 673, XP009046979, ISSN: 1076-1551
- [YP] JACKSON R S ET AL: "Proopiomelanocortin products and human early-onset obesity.", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, FEB 1999, vol. 84, no. 2, February 1999 (1999-02-01), pages 819 - 820, XP002326389, ISSN: 0021-972X
- [Y] MIZUNO T M ET AL: "HYPOTHALAMIC PRO-OPIOMELANOCORTIN MRNA IS REDUCED BY FASTING IN OB/OB AND DB/DB MICE, BUT IS STIMULATED BY LEPTIN", DIABETES, NEW YORK, NY, US, vol. 47, no. 2, February 1998 (1998-02-01), pages 294 - 297, XP001063909, ISSN: 0012-1797
- [Y] CHEUNG C C ET AL: "PROOPIOMELANOCORTIN NEURONS ARE DIRECT TARGETS FOR LEPTIN IN THE HYPOTHALAMUS", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 138, no. 10, 1997, pages 4489 - 4492, XP009027762, ISSN: 0013-7227
- [Y] BOSTON BRUCE A ET AL: "Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line", ENDOCRINOLOGY, vol. 137, no. 5, 1996, pages 2043 - 2050, XP002326390, ISSN: 0013-7227
- [Y] BERTAGNA XAVIER: "Proopiomelanocortin-derived peptides", ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, vol. 23, no. 3, 1994, pages 467 - 485, XP009046900, ISSN: 0889-8529
- See references of WO 0033658A1

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 0033658 A1 20000615**; AU 3117600 A 20000626; CA 2353776 A1 20000615; EP 1137340 A1 20011004; EP 1137340 A4 20051221; JP 2003520015 A 20030702; MX PA01005818 A 20030721

DOCDB simple family (application)

**US 9929337 W 19991209**; AU 3117600 A 19991209; CA 2353776 A 19991209; EP 99965208 A 19991209; JP 2000586172 A 19991209;  
MX PA01005818 A 19991209